AI assistant
CAMBIUM BIO LIMITED — Investor Presentation 2021
Feb 24, 2021
64666_rns_2021-02-24_46748b97-e304-4280-935b-61d75e50ee8b.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [144 x 30] intentionally omitted <==
ASX Announcement
25 February 2021
Regeneus (ASX: RGS) Company Update Investor Webcast Notification
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, today advises it will be conducting a live webcast and Q&A with Regeneus CEO Karolis Rosickas on Wednesday 3 March at 11:00am Australian Eastern Daylight Time (AEDT).
Investors are invited to join the session where Mr. Rosickas will provide an update on the Company’s technology and ongoing strategy. Please note, the webinar will not cover financial updates.
To register for the webcast, please follow this link: https://us02web.zoom.us/webinar/register/WN_YyKYF3USS0WusNbNBlafAQ
Investors are invited to submit questions relating to the Company’s technology ahead of the webcast by emailing [email protected].
Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.
- ENDS -
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza™ and Sygenus. Visit www.regeneus.com.au for more information.
Authorisation & Additional information
Investor and Media Contact
This announcement was authorised by WE Communications the Board of Directors of Regeneus Ltd T: (03) 8866 1200 E: [email protected]
2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358